Stock Events

Stock Events

X.T.L. Biopharmaceuticals 

$2.49
0
-$0.22-8.12% Wednesday 02:45

Statistics

Day High
2.49
Day Low
2.36
52W High
-
52W Low
-
Volume
14
Avg. Volume
-
Mkt Cap
2.19B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-227.72%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
902,000Revenue
-2.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XTLB.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in similar therapeutic areas as XTLB, including treatments for viral diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics and has developed products in areas that overlap with XTLB's research interests, such as immunology and inflammation.
Biogen
BIIB
Mkt Cap22.63B
Biogen develops therapies for neurological and neurodegenerative diseases, competing directly with XTLB's focus on autoimmune diseases and immunotherapy.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals concentrates on creating drugs for complex diseases, a similar approach to XTLB's focus on targeted therapeutic applications.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with XTLB in the field of biologic therapies.
Incyte
INCY
Mkt Cap18.35B
Incyte specializes in oncology and inflammation, aligning closely with XTLB's research into immune response modulation.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that develops treatments across a broad range of areas, including those targeted by XTLB.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates across various therapeutic areas, including immunology and oncology, overlapping with XTLB's therapeutic development strategies.

About

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Show more...
CEO
ISIN
US98386D3070

Listings

F
DE
HHB0.F
XNAS
US
XTLB
BOATS
BOATS
XTLB.BOATS
F
DE
H2K2.F

0 Comments

Share your thoughts

FAQ

What is X.T.L. Biopharmaceuticals stock price today?▼
The current price of XTLB.BOATS is $2.49 USD — it has decreased by -8.12% in the past 24 hours. Watch X.T.L. Biopharmaceuticals stock price performance more closely on the chart.
What is X.T.L. Biopharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange X.T.L. Biopharmaceuticals stocks are traded under the ticker XTLB.BOATS.
What is X.T.L. Biopharmaceuticals market cap?▼
Today X.T.L. Biopharmaceuticals has the market capitalization of 2.19B
What is X.T.L. Biopharmaceuticals revenue for the last year?▼
X.T.L. Biopharmaceuticals revenue for the last year amounts to 902,000 USD.
What is X.T.L. Biopharmaceuticals net income for the last year?▼
XTLB.BOATS net income for the last year is -2.05M USD.
When did X.T.L. Biopharmaceuticals complete a stock split?▼
The last stock split for X.T.L. Biopharmaceuticals was on March 25, 2026 with a ratio of 1:4.